Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Redefining cancer: a new paradigm for better and faster treatment innovation.

Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique - 1 Jan 2014

Stewart David J, Batist Gerald

Abstract excerpt

Common cancers may arise from several different mutations, and each causative mutation may require different treatment approaches. There are also several mechanisms by which malignancies may become resistant to therapy, and each mechanism will also require a different therapeutic strategy. Hence,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Time Factors
Share to Antineoplastic Agents
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Approval

Share to Drug Design

Share to Drug Resistance, Neoplasm

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 24671868

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24671868-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Redefining cancer: a new paradigm for better and faster treatment innovation.PMID 24671868Read ↗

Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases.Semantic proximity Read ↗

Designing Transformative Clinical Trials in the Cancer Genome EraSemantic proximity Read ↗

Advancements in Cancer TreatmentsSemantic proximity Read ↗

Novel clinical trial designs emerging from the molecular reclassification of cancerSemantic proximity Read ↗

Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor ProgressionSemantic proximity Read ↗

Targeting molecular subtypes in solid cancers: successes and failures.Semantic proximity Read ↗

New approaches to molecular cancer therapeuticsSemantic proximity Read ↗

Computational Approaches to Accelerating Novel Medicine and Better Patient Care from Bedside to Benchtop.Semantic proximity Read ↗

Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints.Semantic proximity Read ↗

Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.Semantic proximity Read ↗

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.Semantic proximity Read ↗

Identifying and Targeting the Cause of Cancer is Needed to Cure CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.